PsA has been shown to have a negative impact on patients’ quality of life (QoL). PsA is the most prevalent extra-cutaneous manifestation in patients with psoriasis, affecting between 8 and 42% of psoriatic patients. It is a complex diseasewhich, in addition to the cutaneous involvement, the patient presents musculoskeletal problems (related to the spine, enthesis and peripheral joints) and may also present extra-muscular manifestations including the intestine or the eye. Psoriatic arthritis (PsA) is a chronic inflammatory disease that is part of the group of spondyloarthropathies, affecting up to 1% of the population. Psoriatic arthritis Quality of life Validation Translation The new measure will be a valuable new tool for use in routine PsA practice and clinical trials. The Brazilian PsAQoL was found easy to understand and complete and has excellent reliability and construct validity. Internal consistency and reproducibility were both excellent for the new adaptation (0.91 and 0.90 respectively Scores on the PsAQoL were found to correlate as expected with the comparator measure and the instrument was able to detect differences in score related to perceived severity of PsA, general health status and presence of a flare. The survey included the Nottingham Health Profile (NHP) as a comparator instrument. Finally, a test-retest validation study was conducted with 52 patients with PsA. This translation then checked for face validity and construct validity with new samples of patients. The UK PsAQoL was translated into Brazilian Portuguese using two translation panels.
The primary objective was to develop and validate a Brazilian Portuguese version of the PsAQoL. The Psoriatic Arthritis Quality of Life Questionnaire (PsAQoL) was the first disease-specific tool for determining the impact of the disease on the quality of life of people with PsA. Psoriatic arthritis (PsA) is a multifaceted inflammatory disease that can cause joint destruction and impair quality of life.
0 kommentar(er)
